Italia markets closed

Instil Bio, Inc. (TIL)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
10,69-0,35 (-3,17%)
Alla chiusura: 04:00PM EDT
11,15 +0,46 (+4,30%)
Dopo ore: 06:29PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente11,04
Aperto11,02
Denaro0,00 x 0
Domanda0,00 x 0
Min-Max giorno10,58 - 11,02
Intervallo di 52 settimane6,08 - 12,98
Volume4.784
Media Volume11.353
Capitalizzazione69,527M
Beta (mensile su 5 anni)1,18
Rapporto PE (ttm)N/D
EPS (ttm)-18,97
Prossima data utili12 ago 2024 - 16 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A20,33
  • GlobeNewswire

    Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

    ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of pat

  • GlobeNewswire

    Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

    Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITIL-306 anticipated in 2024 DALLAS, June 26, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the